Sofosvel is the global first generic oral tablet for pan-genotypic Chronic Hepatitis C treatment. This combination (Sofosbuvir 400 mg + Valpatasvir 100 mg) drug has been approved by US FDA & European Commission for treatment of patients with all genotypic Chronic Hepatitis C virus infection.
Sofosvel is used without cirrhosis or with compensated cirrhosis, and patients with advanced cirrhosis (Decompensated).
“Hepatitis-C Drugs remain unaffordable in many countries”
Beacon Introduces Global Patient Support Program
Life saving drugs are either beyond the reach of general
people or not available in many countries. Because of
the patient exemptions for Bangladeshi companies,
Beacon Pharmaceuticals can manufacture the patented
drugs. As a support to global patient… Read more
Registered & Licensed by Regulatory
Authority of Bangladesh
Sofosvel is a registered product by the Directorate General
of Drug Administration & Licensing Authority (Drugs) of
Bangladesh. Drug Registration Number: 341-294-32
Inclusion Date: 20-07-2016 Valid up to: 19-07-2021
Latest News
US’ Gilead faces competition from Bangladesh’s Beacon pharma
In a classic David Vs Goliath case, the US-based drugmaker Gilead that has made billions of dollars over its blockbuster range of Hepatitis C drugs is facing an unconventional challenger. Beacon Pharma, a little known Bangladeshi drugmaker, has emerged as the David to...
read more
EC Grants Gilead’s Sofosbuvir/Velpatasvir for Chronic Hepatitis C
Gilead Sciences, Inc. (GILD) today announced that the European Commission has granted marketing authorization for Epclusa®, the first pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection. The...
read more
European Commission approves Epclusa for all HCV genotypes
The European Commission approved Gilead Science’s marketing authorization application for Epclusa for the treatment of all chronic hepatitis C genotypes, according to a press release from the manufacturer. Epclusa (sofosbuvir/velpatasvir, Gilead Sciences) is an...
read more